COST-EFFECTIVENESS OF VEDOLIZUMAB FOR THE MANAGEMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS IN THAILAND

被引：0
|
作者：
Sruamsiri, R. [1 ]
机构：
[1] Takeda Thailand Ltd, Bangkok, Thailand
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.07.015
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CE3
引用
收藏
页码：S2 / S2
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF FIRST-LINE BIOLOGICS FOR THE MANAGEMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS
    Beilman, Candace L.
    Fedorak, Richard N.
    Halloran, Brendan P.
    GASTROENTEROLOGY, 2019, 156 (06) : S260 - S261
  • [2] Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis
    Wu, Bin
    Wang, Zhenhua
    Zhang, Qiang
    INFLAMMATORY BOWEL DISEASES, 2018, 24 (11) : 2291 - 2302
  • [3] Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis
    Yokomizo, Lauren
    Limketkai, Berkeley
    Park, K. T.
    BMJ OPEN GASTROENTEROLOGY, 2016, 3 (01):
  • [4] Cost-Effectiveness of Infliximab Scheduled Maintenance Treatment for the Management of Patients With Moderate-to-Severe Ulcerative Colitis
    Monfared, Amir A. Tahami
    Feagan, Brian G.
    GASTROENTEROLOGY, 2013, 144 (05) : S637 - S637
  • [5] Cost-effectiveness analysis of using innovative therapies for the management of moderate-to-severe ulcerative colitis in Spain
    Taxonera, Carlos
    de Andres-Nogales, Fernando
    Garcia-Lopez, Santiago
    Sanchez-Guerrero, Amelia
    Menchen, Belen
    Peral, Carmen
    Cabez, Ana
    Gomez, Susana
    Lopez-Ibanez de Aldecoa, Alejandra
    Casado, Miguel Angel
    Menchen, Luis
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (01) : 73 - 83
  • [6] Cost-effectiveness analysis of infliximab, adalimumab, golimumab and vedolizumab for moderate to severe ulcerative colitis in Spain
    Trigo-Vicente, Cristina
    Gimeno-Ballester, Vicente
    Montoiro-Allue, Raquel
    Lopez-Del Val, Alejandro
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2018, 18 (03) : 321 - 329
  • [7] Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
    Sands, Bruce E.
    Peyrin-Biroulet, Laurent
    Loftus, Edward V., Jr.
    Danese, Silvio
    Colombel, Jean-Frederic
    Toruner, Murat
    Jonaitis, Laimas
    Abhyankar, Brihad
    Chen, Jingjing
    Rogers, Raquel
    Lirio, Richard A.
    Bornstein, Jeffrey D.
    Schreiber, Stefan
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (13): : 1215 - 1226
  • [8] Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis
    Tribich, Samuel
    Maurice, James
    FRONTLINE GASTROENTEROLOGY, 2020, 11 (02) : 173 - 173
  • [9] Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
    Biemans, Vince B. C.
    Hoentjen, Frank
    Pierik, Marieke J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (01): : 92 - 92
  • [10] Cost-Effectiveness Analysis of Vedolizumab Compared With Infliximab in Anti-TNF-α-Naive Patients With Moderate-to-Severe Ulcerative Colitis in China
    Zhou, Ting
    Sheng, Yanan
    Guan, Haijing
    Meng, Rui
    Wang, Zijing
    FRONTIERS IN PUBLIC HEALTH, 2021, 9
12345